|
|
|
|
|
|
by nabla9
2656 days ago
|
|
|
> the top 15 pharma companies spend $75B in r&d Large sum of that money is wasted because incentives are perverse. Developing new molecular entities (NME) that do the same thing as already approved new chemical entity (NCE) just for competitive reasons is wasted R&D from the public health perspective. Evergreening and pay-for-delay costs additional billons for pharma companies and it's just zero-sum game between manufacturers. |
|
|